GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ind-Swift Laboratories Ltd (NSE:INDSWFTLAB) » Definitions » Debt-to-Revenue

Ind-Swift Laboratories (NSE:INDSWFTLAB) Debt-to-Revenue : 0.00 (As of Dec. 2023)


View and export this data going back to 1997. Start your Free Trial

What is Ind-Swift Laboratories Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Ind-Swift Laboratories's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0 Mil. Ind-Swift Laboratories's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0 Mil. Ind-Swift Laboratories's annualized Revenue for the quarter that ended in Dec. 2023 was ₹11,501 Mil. Ind-Swift Laboratories's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.00.


Ind-Swift Laboratories Debt-to-Revenue Historical Data

The historical data trend for Ind-Swift Laboratories's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ind-Swift Laboratories Debt-to-Revenue Chart

Ind-Swift Laboratories Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.52 1.32 1.13 0.92 0.71

Ind-Swift Laboratories Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.71 - 0.69 -

Competitive Comparison of Ind-Swift Laboratories's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Ind-Swift Laboratories's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ind-Swift Laboratories's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ind-Swift Laboratories's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Ind-Swift Laboratories's Debt-to-Revenue falls into.



Ind-Swift Laboratories Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Ind-Swift Laboratories's Debt-to-Revenue for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1089.695 + 7531.321) / 12073.1
=0.71

Ind-Swift Laboratories's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0 + 0) / 11500.572
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.


Ind-Swift Laboratories Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Ind-Swift Laboratories's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Ind-Swift Laboratories (NSE:INDSWFTLAB) Business Description

Traded in Other Exchanges
Address
SCO 850, Shivalik Enclave, NAC, Manimajra, Chandigarh, PB, IND, 160 101
Ind-Swift Laboratories Ltd is engaged in the business of active pharmaceutical ingredients (API). The company caters to diverse therapeutic segments namely Cardiovascular health, Antihistamine, Antidiabetic, Antipsychotic, Parkinson's Disease, Antineoplastic, ADHD Symptoms, Analgesics, Alcohol Abstinence, and Bone Resorption Inhibitor. Geographically, it derives a majority of revenue from Outside India.

Ind-Swift Laboratories (NSE:INDSWFTLAB) Headlines

No Headlines